Atossa Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Atossa Therapeutics, Inc. (ATOS) on October 14, 2025. The filing discloses a significant change in executive leadership, specifically the appointment of a new Chief Financial Officer (CFO) and the departure of the previous CFO.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and employment terms.
Material Changes
- Appointment of New CFO: Mark Daniel was appointed as Chief Financial Officer and Principal Accounting Officer, effective October 14, 2025.
- Departure of Former CFO: Heather Rees ceased serving as CFO and PAO on the Effective Date. She will remain as a non-officer employee until November 15, 2025, to assist with the transition.
- Compensation for New CFO:
- Base Salary: $415,900.
- Annual Performance Bonus: Target of up to 40% of base salary, beginning in fiscal year 2026.
- Equity Grant: Stock option to purchase 578,000 shares of common stock. Vesting schedule includes 25% on the first anniversary and the remaining 75% in equal quarterly installments over the subsequent three years.
- Separation Terms for Former CFO: Ms. Rees will receive nine months of base salary and the employer portion of COBRA health premiums for nine months, contingent upon a release of claims and compliance with restrictive covenants.
Outlook, Risks, and Contingencies
The filing details severance provisions for Mr. Daniel under various termination scenarios:
- Death or Disability: Pro rata bonus payment.
- Termination without Cause or Good Reason (Standard): 50% of base salary over six months and up to six months of COBRA benefits.
- Termination without Cause or Good Reason (Change in Control): Pro rata bonus, a lump sum equal to 1.0 times base salary plus target bonus, full acceleration of equity vesting, and up to twelve months of COBRA benefits.
No specific business risks or operational contingencies were disclosed in this report.
Investor Verification Checklist
- Verify the stock price on October 14, 2025, to determine the exercise price of Mr. Daniel's 578,000 share option grant.
- Review the attached Employment Agreement (Exhibit 10.1) for specific definitions of "Cause," "Good Reason," and "Change in Control."
- Monitor the transition period ending November 15, 2025, for any operational disruptions.
- Check subsequent filings for the establishment of performance goals for Mr. Daniel's 2026 bonus.